| |
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
Today’s Big NewsApr 1, 2025 |
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Health systems around the globe face a difficult paradox: delivering more care with fewer resources. In this exclusive webinar, our expert panel will explore how AI-based solutions are addressing these challenges with real-world examples, experience, and published outcomes in ASCO and Nature. Register now. 
|
|
| By Gabrielle Masson At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting for nearly a third of those rounds. The cuts were accompanied by eight biotech closures as the sector faces deep uncertainty tied to recent geopolitical changes. |
|
|
|
By Eric Sagonowsky Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in his resignation as director of the FDA's Center for Biologics Evaluation and Research. Before that, FDA commissioner Marty Makary signed off on his ouster, according to Politico. |
By Conor Hale The ruling was issued for a pair of lawsuits brought against the FDA by the American Clinical Laboratory Association and the Association for Molecular Pathology. |
By Kevin Dunleavy With the decision of a Texas federal judge to dismiss Johnson & Johnson's third effort to resolve some 90,000 talcum powder lawsuits through a planned $9 billion Chapter 11 settlement, the company said it will abandon its efforts to rectify the cases through bankruptcy proceedings and is ready to take them on in court. |
|
Thursday, April 10, 2025 | 11am ET / 8am PT Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. However, the complexities pose key challenges. In this webinar, learn how to choose the right production platform for achieving commercial timelines and managing manufacturing costs. Register now. 
|
|
By Gabrielle Masson Vence Bonham Jr., the highest ranking official at the National Human Genome Research Institute, has been put on administrative leave. |
By Fraiser Kansteiner As President Donald Trump threatens to impose sweeping geographic tariffs this week and rekindles discussions around industry-specific duties on drugmakers, pharmaceutical makers are lobbying the administration to buy themselves some extra time, Reuters reported Tuesday. |
By James Waldron After a year of stripping back its head count and pipeline, Carisma Therapeutics is winding down operations and laying off any staff “not deemed necessary to pursue strategic alternatives.” |
By Nick Paul Taylor Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated symptoms. |
By Zoey Becker A District Court backed the U.S. government in its ruling that Vertex's fertility support program, which proposed offering up to $70,000 in fertility services for eligible Casgevy patients, would violate anti-kickback statutes. |
By Noah Tong,Dave Muoio The Department of Health and Human Services rescinded $11.4 billion in funds to states, cities and organizations receiving grants for COVID-19 efforts and other public health programs. Meanwhile, the HHS told employees to identify contracts that lead to censorship or misinformation on topics not limited to COVID-19. |
By Andrea Park As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. |
By Conor Hale Picard Medical, which owns and operates the implant manufacturer SynCardia, aims to list on the New York Stock Exchange under the ticker PMI. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Antibody-drug conjugates (ADCs) and radioisotope therapies (RITs) offer targeted therapies that effectively attack tumor cells while minimizing harm to surrounding healthy tissue. However, the right design of ADC and RIT trials is critical. Access this report to learn about the pivotal role of advanced medical imaging. Download here. 
|
|
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
